# Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

> **NCT00286780** · PHASE2 · COMPLETED · sponsor: **Ascenta Therapeutics** · enrollment: 19 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** AT-101

## Key facts

- **NCT ID:** NCT00286780
- **Lead sponsor:** Ascenta Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2010-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00286780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00286780, "Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00286780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*